Tissue engineering is likely to create incremental growth opportunities to the regenerative medicine market across the globe during the assessment period. Increasing demand for next generation tissue obtained biomaterial based technologies is likely to stimulate the growth of regenerative medicine market across the globe. Apart from this, technological innovations with regards to tissue engineering, stem cell therapy and biomaterials will drive the regenerative medicine market across the globe in the near future.
Comprehensive analysis on a larger basis was taken up based on regenerative medicine market by a well-known research company. Analysts who were part of this global report development have precisely mentioned facts and figures on the regenerative medicine market functioning worldwide. According to the analysts, regenerative medicine market will possibly grow at an outstanding CAGR of 11.1% throughout the forecast period, 2015-2019 and touched an evaluation of nearly US$ 4,808.9Mn by the end of 2016.
Key players operating in the regenerative medicine market are inclusive of Baxter International, Inc., Zimmer Holdings, Inc., Medtronic, Inc., Arthrex, Inc., Stryker Corporation, DePuy Synthes, Inc. and Smith & Nephew plc. Key players and the manufacturers in regenerative medicine market have been concentrating on developing strategies that include advancement and innovation of current as well as developing products. This move in turn is likely to be supremely beneficial for end-users on a larger basis.
Baxter International, Inc., Enters into Acquisition Process for Expanding its Product Portfolio
Key players and the manufacturers in regenerative medicine market can note that Baxter International, Inc., has been making big plans to acquire two sealant and hemostat products from the Mallinckrodt plc: RECOTHROM Thrombin topical (Recombinant) as well as PREVELEAK Surgical Sealant. RECOTHROM basically is the one and only recombinant thrombin that is stand-alone. Also, PREVELEAK Surgical Sealant is mainly meant for vascular reconstruction purposes.
Key players and the manufacturers in regenerative medicine market can note that Baxter International, Inc., has been taking immense efforts in identifying solutions for the purpose of meeting various needs of the surgeons. Customers can take into account the point that RECOTHROM can benefit the surgeons for the purpose of facing comparatively less issues regarding severe intraoperative bleeding and the PREVELEAK Surgical Sealant complements the existing product portfolio of Baxter International, Inc., for the purpose of cardiovascular as well as various other surgical specialties.
Insights on RECOTHROM Thrombin topical (Recombinant) & PREVELEAK Surgical Sealant
RECOTHROM Thrombin topical (Recombinant) is holistically utilized by combining with various other hemostats, which are estimated for being utilized in a large number of patients every year in U.S., in order to help the surgeons for addressing cases of intraoperative bleeding in a better way. PREVELEAK Surgical Sealant has been engineered for sealing suture holes that are formed during the surgical repair of circulatory system. Apart from this, PREVELEAK Surgical Sealant has been utilized for reinforcing sutured connections amongst blood vessels. Most of all, this acquisition helps Baxter International, Inc., in expanding its product portfolio and providing surgeons with extra clinically differentiated products for addressing the varying needs of the patients.
A sample of this report is available upon request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1326